Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

The availability of tyrosine kinase inhibitors (TKI) during the past ten years has led to improved response and overall survival of patients suffering from metastatic clear cell renal cell carcinoma (ccRCC). However, most of these tumors will eventually progress due to resistance evolving under ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietz, Steffen, Sültmann, Holger, Du, YueJun, Reisinger, Eva, Riediger, Anja Lisa, Volckmar, Anna-Lena, Stenzinger, Albrecht, Schlesner, Matthias, Jäger, Dirk, Hohenfellner, Markus, Duensing, Stefan, Grüllich, Carsten, Pahernik, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650322/
https://www.ncbi.nlm.nih.gov/pubmed/29088767
http://dx.doi.org/10.18632/oncotarget.18200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650322/
https://www.ncbi.nlm.nih.gov/pubmed/29088767
http://dx.doi.org/10.18632/oncotarget.18200

Ejemplares similares